MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
2007 NOV 12 -- MedImmune, Inc. announced it will present three abstracts at the American Academy of Pediatrics (AAP) 2007 National Conference & Exhibition, adding to the company's growing body of research into the prevention of respiratory syncytial virus (RSV), a leading cause of hospitalization among infants. "MedImmune is pleased to present data that provide key insights into how we can optimize the fight against RSV," said Jessie R. Groothuis, M.D., vice president, medical and scientific affairs, infectious disease. "Cost- effectiveness data help insurers, governments, and families understand the benefits of RSV prophylaxis and the potential impact of not taking preventive measures. Surveillance data help us understand local variants in RSV outbreaks, which can inform and improve RSV prevention guidelines." Keywords: Pediatrics, Biotechnology Business, Biotechnology Company, Infectious Disease, MedImmune Inc., Pediatric, Pulmonology, Respiratory Syncytial Virus, MedImmune Inc. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
